Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment. Restoring balance through PGE2 inhibition and IFN-I enhancement could renew immune defenses and improve immunotherapy outcomes.
Cancer cells block T-cell activation, but new therapies restore immune defenses
- Post author:
- Post published:December 4, 2024
- Post category:uncategorized